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a b s t r a c t
It has been reported that reactive oxygen species (ROS) play a role as intracellular signaling molecules in
RANKL stimulation. Previously we demonstrated that induction of cytoprotective enzyme expression by Nrf2-
gene transfer successfully ameliorated RANKL-dependent osteoclastogenesis. In the present study, we
hypothesized that Nrf2 activation by inhibiting ubiquitination and degradation of Nrf2 by ETGE-peptide
would induce Nrf2-dependent cytoprotective enzyme expression, attenuate ROS signaling, and thereby inhibit
RANKL-dependent osteoclastogenesis. ETGE-peptide containing a cell-permeable sequence (seven consecutive
arginine; 7R-ETGE) was applied to a mouse macrophage cell-line RAW 264.7 cell or a primary macrophage
culture. ETGE-peptide prevents Keap1 from binding to Nrf2. Nrf2 nuclear translocation and Nrf2-dependent
cytoprotective enzyme induction was observed. The effects of 7R-ETGE on RANKL-dependent induction of
intracellular ROS levels and osteoclastogenesis were examined. Finally, the protective effect of 7R-ETGE on
RANKL-mediated bone destructionwas investigated in mice. 7R-ETGE dose-dependently induced nuclear Nrf2,
followed by the induction of cytoprotective enzyme expression at both the gene and protein level. 7R-ETGE
inhibited upregulation of intracellular ROS levels by RANKL stimulation, and osteoclastogenesis was
attenuated. Of particular interest was that local injection of 7R-ETGE ameliorated RANKL-mediated bone
destruction. Local induction of nuclear Nrf2 by protein transduction is a potential novel therapeutic target for
bone destruction diseases such as periodontitis and rheumatoid arthritis.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).\
Introduction
Oxidative stress is thought to be one of the drivers of bone
destructive disease such as periodontitis [1], and reactive oxygen
species (ROS) play a role in osteoclastogenesis as intracellular
signaling molecules following RANKL signaling [2]. It is well known
that ROS act not only as intracellular signaling molecules, but also
exert cytotoxic effects such as peroxidation of lipids and phospho-
lipids [3], and oxidative damage to proteins and DNA [4]. Therefore,
cells have several protective mechanisms against these oxidative
stressors [5]. Transcriptional factor nuclear factor E2-related factor 2
(Nrf2) transcriptionally controls the gene expression of many cyto-
protective enzymes, such as heme oxygenase-1 (HO-1) [6], NAD(P)H:
quinone reductase (NQO1) [7], gamma-glutamylcysteine synthetase
(GCS) [8], and glucose 6-phosphate dehydrogenase (G6PD) [9]. These
cytoprotective enzymes exhibit ROS scavenging ability [10–13].
Previously we reported that the Keap1/Nrf2 axis regulates RANKL-
dependent osteoclastogenesis through modulation of intracellular ROS
signaling by the expression of cytoprotective enzymes [14]. More
importantly, in vivo local Nrf2-gene transfer signiﬁcantly inhibited
RANKL-mediated osteoclastogenesis. These results stimulated the
experimental idea to attenuate RANKL-mediated osteoclastogenesis
by inhibiting ROS signaling with the activation of Nrf2-dependent
cytoprotective enzyme expression.
The fate of Nrf2 is strictly regulated by kelch-like ECH-associated
protein 1 (Keap1), and Nrf2-dependent transcription of cytoprotec-
tive enzymes is negatively regulated by inhibition of Nrf2 nuclear
translocation, with cytoplasmic ubiquitination and degradation of
Nrf2 [15]. During this step, Keap1 binds to the ETGE sequence
(LQLDEETGEFLPIQ) of Nrf2, and ubiquitinate Nrf2 [16].
In the present study, we hypothesized that Nrf2 activation, by
protecting Nrf2 from Keap1-mediated ubiquitination and degradation,
would increase Nrf2-dependent expression of cytoprotective enzymes,
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and they would scavenge ROS, and therefore attenuate RANKL
signaling and osteoclastogenesis. To examine this hypothesis, we used
a synthesized peptide whose sequence (ETGE sequence) is identical to
the binding domain of Nrf2 to Keap1, and prevents Keap1 from bind-
ing to Nrf2, thereby protecting Nrf2 from ubiquitination and degrada-
tion [16]. We were particularly interested in examining whether
the peptide can attenuate RANKL-mediated osteoclastogenesis both
in vitro and in vivo.
Material and Methods
Cells
Mouse cells from the RAW 264.7 monocytic cell line
RAW 264.7 cells were obtained from the Riken BioResource
Center (Tsukuba, Japan).
Mouse primary peritoneal macrophages
Three C57/B6 mice (Japan SLC Inc., Hamamatsu, Japan) were
sacriﬁced, and cold phosphate-buffered saline solution (PBS) was
injected into their peritoneal cavities. Peritoneal lavage ﬂuid was
collected and centrifuged to harvest cells. The cells recovered from
the precipitated pellet were pre-cultured with 50 ng/ml of recombi-
nant macrophage colony-stimulating factor (M-CSF; Wako Pure Che-
mical Industries, Ltd., Osaka, Japan) for 4 days and the attached cells
were used as peritoneal macrophages [17]. Recombinant M-CSF
(20 ng/ml) was added to the culture medium.
Cell culture
Cells were cultured in alpha-modiﬁed Eagle Medium (α-MEM;
Wako Pure Chemical Industries, Ltd., Osaka, Japan) containing 10%
(V/V) fetal bovine serum (HyClone; Thermo Scientiﬁc, South
Logan, UT) supplemented with antibiotics (100 U/ml penicillin
and 100 μg/ml streptomycin). All cells were cultured at 37 1C in a
5% CO2 incubator.
Construction of ETGE-peptide
The ETGE-peptide (LQLDEETGEFLPIQ) sequence is identical to the
binding domain of Nrf2 to ubiquitination facilitator protein Keap1, and
inhibits Keap1 from binding to Nrf2 [16]. ETGE-peptide and ETGE-
peptide containing the cell-permeable sequence (seven consecutive
arginine; 7R-ETGE: RRRRRRRRLQLDEETGEFLPIQ) were synthesized
(Medical & Biological Laboratories Co., Ltd, Nagoya, Japan). Also, 7R
peptide (RRRRRRR) was synthesized (PH Japan, Hiroshima, Japan).
These peptides were dissolved in N,N-dimethylformamide (DMF) at a
concentration of 50 mM and stored in a freezer. In the preliminary
experiments, we compared control cells and DMF treated cells and
observed no prominent difference including ROS production in vitro
experiments (data not shown), and set no DMF control group in the
series of in vitro experiments.
Osteoclastogenesis assay
RAW 264.7 cells were plated onto 96-well plates at a density of
103 cells/well, in the presence or absence of recombinant sRANKL
(100 ng/ml ﬁnal concentration; Wako Pure Chemical Industries, Ltd.)
with or without ETGE-peptides or 7R peptide (50 μM ﬁnal, each).
Mouse primary peritoneal macrophages (104 cells/well) were plated
onto 96-well plates, in the presence or absence of recombinant
sRANKL (100 ng/ml ﬁnal concentration; Wako Pure Chemical Indus-
tries, Ltd.) and M-CSF (20 ng/ml) with or without ETGE-peptides
(50 μM ﬁnal). After 4days culture, cells were stained for tartrate-
resistant acid phosphatase (TRAP) using an acid phosphatase kit
(Sigma Chemical Co., St Louis, MO) according to the manufacturer's
instructions. Dark-red multi-nucleated cells (Z3 nuclei) were counted
as TRAP-positive multi-nucleated cells.
Real-time PCR analysis
In some experiments, RNA was extracted using the GenElute
Mammalian Total RNA Miniprep Kit (Sigma-Aldrich Co., St Louis,
MO) with on-column DNA digestion according to the manufac-
turer's instructions. After measurement of the RNA concentration,
isolated RNA (100 ng each) was reverse transcribed with iScript
cDNA Supermix (Bio-Rad Laboratories, Hercules, CA), and cDNA
stock was diluted (5) with Tris-EDTA (TE) buffer. Real-time RT-
PCR was performed with SsoFast EvaGreen Supermix (Bio-Rad
Laboratories) using a CFX96 instrument (Bio-Rad Laboratories).
The PCR primers used in the experiments have been described
elsewhere [14]. Fold changes of gene of interest were calculated
with ΔΔCt method using ribosomal protein S18 (RPS18) as
reference gene [19].
Resorption assay
RAW 264.7 cells were seeded on synthesized calcium phos-
phate substrate (bone resorption assay plate; PG Research, Tokyo,
Japan) and stimulated with RANKL (100 ng/ml) in the presence or
absence of ETGE peptides (50 μM ﬁnal). After 7 days' cultivation,
cells were removed with bleach, and the calcium phosphate
substrate was washed with distilled water and then dried. Photo-
graphs were taken, and the average of the resorbed area per ﬁeld
was calculated from twelve images of each sample, using Image-J
software (National Institutes of Health, Bethesda, MD).
Intracellular ROS detection
Intracellular ROS levels were detected using the Total ROS/
Superoxide Detection Kit (Enzo Life Sciences Inc., Farmingdale, NY,
USA), according to the manufacturer's instructions. The ROS
detection dye in the kit reacts directly with a wide range of
reactive species, such as hydrogen peroxide (H2O2), peroxynitrite
(ONOO-), hydroxyl radicals (HO  ), nitric oxide (NO), and peroxy
radical (ROO  ). Cells were pre-cultured with or without ETGE-
peptide (50 μM ﬁnal) for 24 h, and then washed with PBS. Cells
were stimulated with sRANKL for 6 h, washed and collected in PBS
supplemented with 2% fetal bovine serum (FBS). The cell suspen-
sion was incubated with oxidative stress detection reagent for
30 min on ice. After washing with PBS, intracellular ROS were
detected using an Accuri C6 ﬂow cytometer (BD Biosciences,
Franklin Lakes, NJ). The viable monocyte/macrophage fraction
was gated on an FSC/SSC plot, and ROS levels were monitored in
the FL-1 channel.
Additionally, we used the cell-permeable speciﬁc H2O2 probe
(BES-H2O2-Ac; Wako) [20] and speciﬁc superoxide probe (BES-So-
AM; Wako) [21] to detect each reactive oxygen species, respec-
tively. Brieﬂy, these probe were dissolved in dimethylformamide,
and used at the ﬁnal concentration of 5 μM, and ﬂuorescence were
monitored in the FL-1 channel.
Preparation of nuclear protein lysate
Nuclear protein lysate was prepared from RAW 264.7 cells
using the DUALXtract cytoplasmic and nuclear protein extraction
kit (Dualsystems Biotech AG, Schlieren, Switzerland) according to
the manufacturer's instructions. Cultured cells were washed with
PBS and treated with cell lysis buffer. After centrifugation, super-
natant of this step was used as cytoplasmic protein samples, and
the nuclear pellet was washed twice and lysed with nuclear lysis
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reagent. After centrifugation, the cleared supernatant was used as
the nuclear protein extract. The protein concentrations of each of
the nuclear lysates were measured with the Quick Start Protein
Assay Kit (Bio-Rad Laboratories), and the concentrations were
adjusted to be the same. After mixing with 4 sample buffer
containing beta-mercaptoethanol, the samples were heat-
denatured at 70 1C for 10 min.
Western blot analysis for Nrf2
The prepared nuclear lysates, containing equal amounts of
protein, were electrophoresed on a TGX Precast gel (BioRad
Laboratories), and the proteins transferred to a polyvinylidene
diﬂuoride (PVDF) membrane using an iBlot blotting system (Life
Technologies Japan Ltd., Tokyo, Japan). The transferred membrane
was treated with Qentix Western Blot Signal Enhancer (Thermo
Fisher Scientiﬁc Inc., Rockford, IL) according to the manufacturer's
instructions. After washing with deionized water, the membrane
was blocked with BlockAce (DS Pharma Biomedical Inc., Osaka,
Japan) for 30 min, and then incubated for 1 h with rabbit IgG anti-
Nrf2 antibody (Santa Cruz Biotechnology Inc.) in Can Get Signal
Solution-1 (Toyobo Co. Ltd, Tokyo, Japan). After thorough washing
with PBS containing 0.5% Tween-20 (PBS-T), the membrane was
incubated for 1 h with horseradish peroxidase (HRP)-conjugated
protein A/G (Thermo Fisher Scientiﬁc Inc.) in Can Get Signal
Solution-2 (Toyobo Co. Ltd), and washed with PBS-T. Chemilumi-
nescence was produced using Luminata Forte (EMD Millipore
Corporation, Billerica, MA) and detected with an ImageQuant
LAS-4000 digital imaging system (GE Healthcare Japan, Tokyo,
Japan). To conﬁrm the equivalence of loaded nuclear protein, the
membrane was re-probed with Restore Plus Western Blot Stripping
Buffer (Thermo Fisher Scientiﬁc Inc.) for 15 min, washed, blocked, and
then blotted in anti-histone H3 antibody (Cell Signaling Technology
Japan, Tokyo, Japan) followed by HRP-conjugated protein A/G.
Western blot analysis for HO-1, NQO1, and GCS.
Cytoplasmic protein samples were used for the detection of HO-1,
NQO1, and GCS using different membranes. The antibodies used in
these experiments were anti HO-1 antibody (StressMarq Biosciences
Inc, Victoria, BC), anti-NQO1 antibody (Abcam plc, Cambridge, MA)
and anti-GCS antibody (Thermo Fisher Scientiﬁc Inc.). To conﬁrm the
equivalence of loaded cytoplasmic protein, TGX Stain-Free Precast Gels
(BioRad Laboratories) were used for cytoplasmic protein samples.
Proteins in the electrophoresed gel were visualized with ultra violet
(UV) treatment before transfer to a PVDF membrane. Visualized
protein on the membrane was imaged with an ImageQuant LAS-
4000 under UV transillumination, and the value of the total protein
band density was used for calibration.
Immunoprecipitation against Keap1
RAW 264 cells were preloaded 7R-ETGE (50 μM ﬁnal) for 1 h,
and then stimulated with RANKL (100 ng/mL ﬁnal) for 3 h, and
cytoplasmic and nuclear protein samples were prepared as
described above. Cytoplasmic protein samples of RANKL-treated
cells and 7R-ETGE/RANKL-treated cells were immunoprecipitated
against Keap1 using anti Keap1 antibody (AVIVA systems biology,
San Diego, CA). Brieﬂy, 50 ng of cytoplasmic protein samples and
2 μg of antibody were incubated on ice with gentle shaking for
9 hours, and further incubated with antibody puriﬁcation mag-
netic beads (recombinant protein A-derivatives conjugated mag-
netic beads: Ab-Capcher Mag; ProteNova Inc., Tokushima, Japan)
for 2 hours. Then magnetic beads were separated, washed with
PBS-T, and bound protein samples were eluted with tricine sample
buffer (BioRad Laboratories) containing 2% β-mercaptoethanol
(Sigma) with heat treatment (90 1C 15 min). Eluates were then
used for western blot analysis for Nrf2 as described above with
slight modiﬁcation of using the EasyBlot anti Rabbit IgG-HRP
conjugated (GeneTex, Irvine, CA) as secondary antibody for the
purpose of decreasing the interference caused by the heavy and
light chains of the IgG used for immunoprecipitation.
Detection of phospho-NF-κB
RAW 264 cells were preloaded 7R-ETGE (50 μM ﬁnal) for 1 h,
and then stimulated with RANKL (100 ng/mL ﬁnal) for 3 h, and
whole cell lysate were prepared using lysis buffer (EDTA (5 mM),
Glycerol (10% v/w), Triton X-100 (1% v/w), SDS (0.1% w/w), and NP-
40 (1% v/w) in PBS) containing proteinase inhibitor cocktail (Roche
Applied science, Tokyo, Japan). Protein concentration of samples
were measured with Micro BCA protein assay kit (Thermo Scien-
tiﬁc inc., Rockford, IL), and the concentrations were adjusted to be
the same. After mixing with 4 sample buffer containing beta-
mercaptoethanol, the samples were heat-denatured at 70 1C for
10 min. Samples were then used for western blot analysis for
phospho-NF-κB as described above using anti phospho-NF-κB p65
antibody (Cell Signaling Technology) for primary antibody.
In addition, to detect phospho-NF-κB by ﬂow cytometry, stimulated
cells were scraped and resuspended into PBS. Then cells were ﬁxed
and permeabilized using FOXP3 Fix/Perm Buffer (Biolegend, San Diego,
CA), washed with FOXP3 Perm Buffer (Biolegend), stained with alexa
Fluor 647-conjugated anti phospho-NF-κB p65 antibody (Beckman
coulter, Brea, CA), and examined by an Accuri C6 ﬂow cytometer.
In vivo bone destruction model
All animal experiment protocols were reviewed and approved by
the Institutional Animal Care and Use Committee (Committee) of the
Tohoku University Environmental & Safety Committee, Japan. Animal
experiments were performed in complying with the Regulations for
Animal Experiments and Related Activities at Tohoku University.
We utilized repeat injections of LPS for our in vivo bone
destruction model [22]. This bone destruction model induces
RANKL-dependent osteoclastogenesis and extensive bone destruc-
tion. Thirty-two, 8-week-old C57B/6 male mice (Japan SLC Inc.,
Hamamatsu, Japan) were used in the experiments. The mice were
randomized into four equal groups: PBS injection group (control
group); 7R-ETGE peptide injected group (7R-ETGE group); LPS-
induced bone resorption group (LPS group); and LPS-induced bone
resorption and 7R-ETGE peptide injected group (LPS þ 7R-ETGE
group). Puriﬁed LPS from Escherichia coli O111:B4 (Sigma Chemi-
cal Co.) was dissolved in PBS at a concentration of 1 mg/mL.
10 mL of LPS solution with 2 mL of DMF or 7R-ETGE peptide
(50 mM) were injected into the animals of LPS group and LPS þ 7R-
ETGE group, respectively. 10 mL of PBS with 2 mL of DMF or 7R-ETGE
peptide (50 mM) were injected into animals in the control and 7R-
ETGE groups, respectively. Injections were performed under anesthe-
sia with a 30-gauge needle at a point on the midline of the skull
located between the eyes, on days 1, 3, 5, 7 and 9. On day 11, the mice
were sacriﬁced by cervical dislocation. RNA from the excised cranial
tissue around the injected site (three RNA samples per group) was
extracted and reverse transcribed (vide supra). Gene expression was
examined by real-time PCR. Other cranial tissue samples (5 samples
per group) were ﬁxed overnight with 4% paraformaldehyde in PBS,
and the specimen was subsequently scanned with an X-ray micro
tomography (microCT) system (ScanXmate-E090; Comscan Tecno Co.,
Ltd., Kanagawa, Japan). The scanned microCT images were reconsti-
tuted using ConeCTexpress software (Comscan Tecno Co., Ltd.). After
reconstitution and obtaining the DICOM ﬁles, 3D-volume rendering
was performed using Pluto software (http://pluto.newves.org/trac).
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Statistical analysis
All data are presented as the mean 7 standard deviation (SD).
All in vitro data are the means of 3 independent experiments.
Multiple comparisons were performed using Tukey's test
(MEPHAS; http://www.gen-info.osaka-u.ac.jp/testdocs/tomocom/
tukey-e.html). po0.05 was considered to be statistically
signiﬁcant.
Fig. 1. 7R-ETGE peptide inhibited osteoclastogenesis. RAW 264.7 cells were stimulated with RANKL for 4 days and TRAP staining was performed. (A) RAW 264.7 cells
stimulated with RANKL (100 ng/ml). (B) RAW 264.7 cells cultured with RANKL and 7R-ETGE peptide. (C) RAW 264.7 cells cultured with RANKL and ETGE peptide. (D) RAW
264.7 cells cultured with RANKL and 7R peptide. Arrowhead indicates TRAPþ multi-nucleated cells. Bar¼100 μm. Representative photographs are shown. (E) The number of
TRAPþ multi-nucleated cells per well was counted. The data shown are representative of three independent experiments performed in triplicate. npo0.05 between groups.
NS: no signiﬁcant difference between groups. Mouse primary peritoneal macrophage were stimulated with M-CSF and RANKL for 4 days and TRAP staining was performed.
(F) Control. (G) Stimulated with RANKL (100 ng/ml). (H) Stimulated with RANKL (100 ng/ml) in the presence of 7R-ETGE peptide. Arrowhead indicates TRAPþ multi-
nucleated cells. Bar¼100 μm. Representative photographs were shown. (I) Number of TRAPþ multi-nucleated cells per well was counted. The data shown are representative
of three independent experiments performed in triplicate. npo0.05 between groups.
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Results
ETGE peptide inhibited osteoclastogenesis and resorption activity
First, we examined whether ETGE peptide had an inhibitory effect
on RANKL-mediated osteoclastogenesis by using RAW 264.7 cells at
day¼4. TRAP staining revealed that 7R-ETGE peptide (Fig. 1B) inhib-
ited RANKL-mediated osteoclastogenesis (Fig. 1A). The number of
TRAP positive multi-nucleated cells was statistically signiﬁcantly
different between RANKL alone and RANKL with 7R-ETGE peptide
(Fig. 1E). There was no statistically signiﬁcant difference between
RANKL alone, RANKL with ETGE peptide (non cell permeable peptide;
Fig. 1C), signifying cell permeable property is necessary for the
inhibition of RANKL-mediated osteoclastogenesis by ETGE peptide. In
addition, no signiﬁcant difference was observed between RANKL alone
and RANKL with 7R peptide (Fig. 1D), signifying cell permeable
peptide sequence, 7R had nothing to do with osteoclastogenesis.
Similar results were obtained using mouse primary peritoneal
macrophages (Fig. 1F-I). 7R-ETGE peptide (Fig. 1H) inhibited RANKL-
mediated osteoclastogenesis (Fig. 1G). The number of TRAP positive
multi-nucleated cells was statistically different between RANKL alone
and RANKL with 7R-ETGE peptide (Fig. 1I).
We further examined the effect of ETGE peptide on RANKL-
mediated osteoclast marker gene induction. 7R-ETGE peptide inhibited
RANKL-mediated inductions of ATP6v0d2, DC-STAMP and OSCAR,
respectively (Fig. 2). These results suggest that 7R-ETGE might inhibit
not only osteoclastogenesis but also osteoclast function.
Next, we examined whether 7R-ETGE peptide shows inhibitory
effect on RANKL-mediated resorption activity. Compared to RANKL
alone (Fig. 3A), 7R-ETGE peptide inhibited RANKL-mediated resorption
activity (Fig. 3B). Non cell permeable ETGE peptide failed to inhibit
RANKL-mediated resorption activity (Fig. 3C). Fig. 3D shows the
percentage area of the assay plate resorbed, and statistical signiﬁcance
was observed between RANKL alone and RANKL with 7R-ETGE. No
statistical difference was observed between RANKL alone and RANKL
with non cell permeable ETGE peptide. These results suggest that cell
permeable 7R-ETGE peptide, but not ETGE peptide can inhibit RANKL-
mediated osteoclastogenesis and osteoclast activation.
7R-ETGE peptide attenuated RANKL-mediated intracellular ROS
Next, we investigated whether 7R-ETGE peptide could interfere
with RANKL-mediated intracellular ROS signaling by using ﬂow
Fig. 2. Osteoclast marker gene expressions were reduced by 7R-ETGE peptide. The
expression of the osteoclast marker genes, ATP6v0d2, DC-STAMP and OSCAR in
RAW 264.7 cells was examined by real-time PCR. The fold increase from the control
is shown. The displayed data are representative of three independent experiments
performed in triplicate. npo0.05 versus stimulation with RANKL alone.
Fig. 3. 7R-ETGE peptide attenuated osteoclastic resorption activity. RAW 264.7 cells
were stimulated with RANKL (100 ng/ml) on synthesized calcium phosphate
substrate for 7 days, and resorption area was analysed. (A) Stimulated with RANKL.
(B) Stimulated with RANKL in the presence of 7R-ETGE peptide. (C) Stimulated with
RANKL in the presence of ETGE peptide. Arrowhead indicates resorbed lacunae.
Bar¼100 μm. Representative photographs are shown. (D) The percentage of the
resorbed area was calculated. The data shown are representative of three inde-
pendent experiments performed in triplicate. npo0.05 versus stimulation with
RANKL alone. NS: no signiﬁcant difference between groups.
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Fig. 4. Flowcytometry analysis for intracellular ROS. Intracellular ROS levels in RAW 264.7 cells were examined using ﬂow cytometry. (A) RANKL induced intracellular ROS.
The red line indicates the control, and the blue line indicates stimulation with RANKL. The data shown are representative of three independent experiments performed in
triplicate. Vertical black line indicates threshold. (B) 7R-ETGE peptide but not ETGE peptide reduced RANKL-induced intracellular ROS in RAW 264.7 cells. The blue line, red
line, and orange line indicate RANKL alone, RANKL with 7R-ETGE peptide, and RANKL with ETGE peptide, respectively. The data shown are representative of three
independent experiments performed in triplicate. Vertical black line indicates threshold. (C) Quantitative analysis for percent of ROS positive in control and RANKL samples.
Percent of ROS positive population judged by the threshold in Fig. 4A were calculated from triplicated samples. nnpo0.01 between samples. (D) Quantitative analysis for
percent of ROS positive in RANKL alone, RANKL with 7R-ETGE peptide, and RANKL with ETGE peptide samples. Percent of ROS positive population judged by the threshold in
Fig. 4B were calculated from triplicated samples. npo0.05 versus RANKL alone. NS: no signiﬁcant difference between groups. (E) RANKL induced intracellular superoxide.
Intracellular superoxide was observed using speciﬁc superoxide probe, BES-So-AM. The the blue line indicates stimulation with RANKL, and red line indicates the RANKL
with 7R-ETGE peptide. The data shown are representative of three independent experiments performed in triplicate. Vertical black line indicates threshold. (F) RANKL
induced intracellular H2O2. Intracellular H2O2 was observed using speciﬁc superoxide probe, BES-H2O2-Ac. The the blue line indicates stimulation with RANKL, and red line
indicates the RANKL with 7R-ETGE peptide. The data shown are representative of three independent experiments performed in triplicate. Vertical black line indicates
threshold. (G) Quantitative analysis for percent of superoxide positive in the samples. Percent of superoxide positive population judged by the threshold in Fig. 4E were
calculated from triplicated samples. npo0.05 between samples. (H) Quantitative analysis for percent of H2O2 positive in the samples. Percent of H2O2 positive population
judged by the threshold in Fig. 4F were calculated from triplicated samples. npo0.05 between samples.
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cytometry. The addition of RANKL induced the formation of
intracellular ROS at 6 h (Fig. 4A and C). This RANKL-mediated
ROS induction was attenuated by 24 h-pretreatment of 7R-ETGE
peptide though that of ETGE peptide had no discernable effects
(Fig. 4B and D). These results suggest that cell permeable 7R-ETGE
peptide attenuates RANKL-mediated intracellular ROS signaling.
To further explore intracellular ROS signaling, we used specifc
superoxide probe and H2O2 probe, and found that 7R-ETGE attenuated
Fig. 5. 7R-ETGE peptide induced Nrf2-mediated upregulation of cytoprotective enzyme expression at both the mRNA and protein level. (A) Western blot analysis for nuclear
Nrf2. Equal amounts of extracted nuclear protein were electrophoresed, transferred onto PDVF membranes, and detected Nrf2 (Top panel). To conﬁrm the equivalence of
loaded nuclear protein, stripped membranes were subjected to western blot analysis using anti Histone H3 antibody (Bottom panel). Densitometry analysis was used to
calculate the ratio relative to the control, and the mean values of three experiments are shown above each panel. (B) 7R-ETGE peptide inhibited Keap1 from the binding to
Nrf2, and increased nuclear translocation of Nrf2. Western blot analysis for Nrf2 of keap1-immunoprecipitated samples from cytoplasm were shown (Top panel). Nuclear
Nrf2 were examined by western blot (Bottom panel). (C) mRNA expression of HO1, NQO1, and GCS were examined by real-time PCR. Fold change of each gene expression
from control were shown. Open bar: control, Close bar: 7R-ETGE treated cells.npo0.05 versus control. The data shown are representative of three independent experiments
performed in triplicate. (D) Western blot analysis for HO1, NQO1, and GCS. Equal amount of cytoplasmic protein were electrophoresed, transferred onto PDVF membrane, and
detected HO1, NQO1, and GCS, respectively. The data shown are representative of three independent experiments. Separate lanes from the same blots had been spliced
together, and line indicate the places at which the lanes were joined. (E) Densitometry analysis of each band as shown in Fig. 5D were used to calculate each relative
expression ratio of HO1, NQO1 and GCS compared to the control. These values were normalized with respect to the amount of whole protein. The mean values from three
experiments are shown. Open bar: control, Close bar: 7R-ETGE treated cells. npo0.05 versus control. (F) Western blot analysis for phosphorylated NF-κB. Equal amount of
whole protein were electrophoresed, transferred onto PDVF membrane, and detected phosphorylated NF-κB using phosphorylated NF-κB speciﬁc antibody. Densitometry
analysis was used to calculate the ratio relative to the control, and the mean values of three experiments are shown above each panel. (G) Flowcytometry analysis for
phosphorylated NF-κB. Each cells were stained with ﬂuorophore labeled different anti phospho-NF-κB p65 antibody and observed by ﬂow cytometer. The blue line, red line,
and orange line indicate control, RANKL alone, and RANKL with 7R-ETGE peptide, respectively. The data shown are representative of three independent experiments
performed in triplicate. Vertical black line indicates threshold. (H) Quantitative analysis for percent of phospho-NF-κB positive in the samples. Percent of phospho-NF-κB
positive population judged by the threshold in Fig. 5G were calculated from triplicated samples. npo0.05 between samples.
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both RANKL-mediated superoxide (Fig. 4E and G) and H2O2 induction
(Fig. 4F and H).
7R-ETGE peptide dose-dependently induced nuclear Nrf2
To understand further the mechanism of the inhibition of
RANKL-mediated osteoclastogenesis by 7R-ETGE peptide, we
examined nuclear Nrf2 by western blot analysis (Fig. 5A). Treat-
ment with 7R-ETGE peptide for 24 h dose-dependently induced
nuclear Nrf2. Then because we presumed 7R-ETGE peptide would
inhibit the binding of Nrf2 and Keap1 and thereby translocate into
nuclear, the binding of Nrf2 to keap1 in cytoplasmwere examined.
Immunoprecipitation using same amount of protein for input
revealed that 7R-ETGE treatment signiﬁcantly attenuated the
formation of Keap1-Nrf2 complex in cytoplasm (Fig. 5B top panel).
Oppositely, nuclear Nrf2 was increased by 7R-ETGE treatment.
These results suggest that 7R-ETGE peptide would mimic ETGE
sequence of Nrf2, bind to Keap1 instead of Nrf2, augment the
translocation of Nrf2 to nucleus, and favor Nrf2-dependent tran-
scription of cytoprotective enzymes.
7R-ETGE peptide upregulated cytoprotective enzyme expression at
both the mRNA and protein level
Next, the effect of 7R-ETGE peptide on the expression of cytopro-
tective enzymes were examined. Real-time PCR analysis revealed that
all three genes, HO1, NQO1, and GCS, were upregulated by 7R-ETGE
peptide treatment (Fig. 5C). Consistent with the mRNA upregulation,
protein level upregulation were unequivocally detected using western
blot analysis (Fig. 5D). Relative band intensity normalized with total
protein indicated 2.1-, 7.2-, and 6.8-fold increases in HO1, NQO1,
and GCS expression after 7R-ETGE treatment, respectively (Fig. 5E).
These results suggest that 7R-ETGE peptide can upregulate cytopro-
tective enzyme expression via Nrf2-dependent transcription.
Interference on RANKL-mediated NF-κB signaling by 7R-ETGE peptide
To further explore the interference on intracellular RANKL signaling
by 7R-ETGE, we examined the essential signaling pathway, NF-κB.
Western blot analysis revealed that RANKL-mediated phosphorylation
of NF-κB was attenuated by 7R-ETGE treatment (Fig. 5F). Similar
results were obtained by ﬂowcytometry using ﬂuorophore-labeled
different anti phospho-NF-κB antibody (Fig. 5G and H). These results
suggest that the NF-κB signaling could be the downstream of RANKL-
mediated ROS signaling.
7R-ETGE peptide inhibited bone destruction in experimental animals
Finally, we determined whether 7R-ETGE peptide ameliorates
RANKL-mediated bone destruction in vivo. Repeat LPS injection
upregulated osteoclastogenic cytokine mRNA, RANKL and TNF-α
(Fig. 6A). This RANKL and TNF-α augmentation led to the upregu-
lation of osteoclast marker genes such as MMP9 and TRAP,
signifying the induction of osteoclastic bone destruction. 7R-
ETGE peptide signiﬁcantly reduced both osteoclastogenic cytokine
and osteoclast marker gene expression. These results suggest that
7R-ETGE peptide attenuated osteoclastogenesis even in vivo.
MicroCT analysis revealed that repeated LPS injections induced
extensive resorption of cranial bone (Fig. 6B). 7R-ETGE peptide
ameliorated LPS-induced RANKL-mediated bone destruction. The
calculated resorbed area in the cranial bone revealed that there is
a statistically signiﬁcant difference between LPS alone and LPS
with 7R-ETGE peptide (Fig. 6C). In addition, there is no statistically
signiﬁcant difference between the control, and LPS with 7R-ETGE
peptide, signifying 7R-ETGE peptide almost completely inhibited
Fig. 6. ETGE peptide inhibited bone destruction in experimental animals. LPS (10 μg/site) or PBS were injected 5 times into each mouse every other day, with or without 7R-
ETGE peptide. (A) Real-time PCR analysis was performed using three RNA samples per group. Fold change from control are shown. npo0.05 between groups. (B) MicroCT
images were taken using 5 samples per group, and representative photographs are shown. Arrowheads indicate resorbed lacunae or holes formed in the cranial bone.
Bar¼1 mm. (C) The resorbed area in the cranial bone was calculated using Image-J software. Mean values are shown for the percentage resorbed (calculated from the ratio of
the number of pixels in the resorbed area in the cranial bone to the number of pixels in the cranial bone in the analyzed image). npo0.05 versus control. NS: no signiﬁcant
difference versus control. †:po0.05 between groups.
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LPS-induced RANKL-mediated bone destruction. These data sug-
gest that 7R-ETGE peptide could inhibit RANKL-mediated osteo-
clastogenesis not only in vitro but also in vivo.
Discussion
In the present study, we discovered that 7R-ETGE peptide could
inhibit osteoclastogenesis in vitro and in vivo. Additionally, we
clariﬁed the inhibitory mechanism of 7R-ETGE peptide on RANKL-
mediated osteoclastogenesis as follows; 1) 7R-ETGE peptide mimics
the ETGE sequence of Nrf2, and Keap1 binds to 7R-ETGE peptide
instead of Nrf2. This leads the attenuation of Nrf2 degradatation, and
induces nuclear translocation of Nrf2. 2) Nuclear translocated Nrf2
transcriptionally increases the Nrf2-dependent expression of cyto-
protective enzymes such as HO1, GCS and NQO1. 3) Upregulated
cytoprotective enzymes scavenge ROS, intracellular signaling mole-
cules of RANKL. 4) Attenuated ROS signaling gives the reduction of
RANKL-mediated osteoclastogenesis. We also tested the effect of
Nrf2 activation on osteoclastogenesis using chemical Nrf2 activator
sulforaphane and Epigallocatechin-3-gallate, and found that both
Nrf2 activator attenuated osteoclastogenesis (Data not shown).
Additionally, sulforaphane was reported as osteoclastogenesis inhi-
bitor via Nrf2 activation [23] and via another pathway [24]. Taken
together, Nrf2 activation and thereby upregulation of cytoprotective
enzyme would attenuate ROS signaling in RANKL-mediated osteo-
clastogenesis. Among cytoprotective enzymes, HO-1 is known to be
able to catalyze heme, and produces biliverdin, iron, and carbon
monoxide, that have anti-oxidative functions [25]. We assume that
the upregulated cytoprotective enzymes decrease intracellular ROS
levels, thereby attenuating ROS-mediated RANKL signaling.
Regarding the intracellular signaling of RANKL, various signaling
pathway for osteoclast differentiation, function, and survival were
reported. Which includes Akt, NFATc1, NF-κB, JNK, ERK, and p38 [26].
Of them, as the name of RANKL suggests (receptor activator of NF-κB
ligand), RANKL mediates NF-κB signaling during osteoclastogenesis
[27]. Our results revealed the interference of NF-κB signaling by 7R-
ETGE with the attenuation of intracellular ROS signaling via induction
of cytoprotective enzymes. Consistent with our results, Bharti et al.
reported that curcumin, which has ROS-scavenging property, inhibits
RANKL-induced NF-κB activation [28]. Taken together, the NF-κB
signaling could be the downstream of RANKL-mediated ROS signaling,
or ROS signaling could be the modulator of NF-κB signaling.
ETGE peptide (LQLDEETGEFLPIQ), whose sequence is identical to
the binding domain of Nrf2 to Keap1, inhibits Keap1 from binding to
Nrf2 by working as decoy molecule against Keap1, thereby protect-
ing Nrf2 from ubiquitination and degradation [16]. The 7R-ETGE
peptide showed anti-osteoclastogenic activity, though ETGE peptide
had no effects. The seven consecutive arginines sequence (7R) we
used is reported that it confers cell permeability [29], and ETGE
peptide without 7R has no cell permeability and fail to inhibit Nrf2
degradation. Consistent with our results, Steel and colleagues also
reported that a cell-penetrating peptide targeting the Nrf2/Keap1
interaction induced HO-1 in a dose-dependent manner, and had an
anti-inﬂammatory effect [30].
The results of our in vitro assay showed a direct inhibitory effect of
7R-ETGE peptide on RANKL-mediated osteoclastogenesis. In addition,
in vivo evaluation of inhibitory effect of 7R-ETGE peptide on bone
resorption revealed that osteoclastic bone resorption was attenuated
both in microCT analysis and osteoclast marker gene expression
measured by realtime PCR. These results indicate that 7R-ETGE
peptide directly acts on osteoclast/precursor cells even in vivo. How-
ever, real-time PCR analysis of RANKL and TNFα gene expression, those
are two major osteoclastogenic cytokines, in RNA samples obtained
from tissue specimen indicated 7R-ETGE peptide can inhibit LPS-
mediated upregulation of osteoclastogenic cytokine expression. As
Kawai et al. reported in inﬂammatory bone destructive diseases such
as periodontitis, a major source of RANKL is from the inﬁltrating
lymphocytes [31]. Although we have not tested the effects of 7R-ETGE
peptide on RANKL expression in lymphocytes, some reports men-
tioned the possibility of developing anti-inﬂammatory therapeutic
targeting of Nrf2 [32,33]. These reports suggest the possibility of the
attenuation of RANKL expression in osteoclastogenesis supporting
cells by 7R-ETGE peptide. Additionally, osteoblasts or other stromal
cells could induce RANKL expression by LPS stimulation [34], and ROS
play a role in RANKL upregulation [35]. Rana et al. reported down-
regulation of RANKL by Nrf2 activation [36]. Furthermore, another
famous osteoclastogenic cytokine TNF-α is downregulated by Nrf2
activation [37]. Therefore, further investigations, especially of potential
indirect effects of 7R-ETGE peptide on osteoclastogenesis – i.e. down-
regulation of osteoclastogenic cytokine expression – will be necessary.
In conclusion, 7R-ETGE peptide can inhibit osteoclastogenesis via
augmentation of Nrf2-dependent cytoprotective enzyme expression
and intracellular ROS scavenging. 7R-ETGE peptide could be useful for
therapeutic approach to the treatment of destructive bone diseases
such as periodontitis and rheumatoid arthritis.
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